Sab Biotherapeutics Inc   (SABS)
Other Ticker:  
Price: $4.4100 $-0.05 -1.121%
Day's High: $4.58 Week Perf: -11.62 %
Day's Low: $ 4.40 30 Day Perf: -26.5 %
Volume (M): 20 52 Wk High: $ 14.50
Volume (M$): $ 88 52 Wk Avg: $7.35
Open: $4.50 52 Wk Low: $0.62

 Market Capitalization (Millions $) 23
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Sab Biotherapeutics Inc
Sab Biotherapeutics Inc. is a biotechnology company that specializes in the development of human antibody therapeutics. They are known for their innovative platform technology, named the DiversitAb' platform, which leverages genetically engineered cattle to produce fully human antibodies.

Using their platform, Sab Biotherapeutics aims to address various diseases and medical conditions, including cancer, infectious diseases, and autoimmune disorders. Their technology enables the production of large quantities of human antibodies in a relatively short period, allowing for more efficient drug development and potentially faster access to life-saving treatments.

The company's approach involves immunizing the genetically engineered cattle with specific antigens, which triggers the production of human antibodies. These antibodies are then harvested and purified for use in therapeutic applications. This unique technology offers several advantages, including improved safety, cost-effectiveness, and increased scalability compared to traditional methods of antibody production.

Sab Biotherapeutics has gained recognition for its work during the COVID-19 pandemic. They have been working on developing a potential treatment for the virus using their DiversitAb' platform. Their product, called SAB-185, is an investigational antibody therapeutic that has shown promising results in preclinical studies. The company is actively collaborating with various partners and regulatory agencies to advance the development and potential approval of this therapy.

In summary, Sab Biotherapeutics Inc. is a biotech company that uses genetically engineered cattle to produce fully human therapeutic antibodies. Their innovative platform technology has the potential to revolutionize the field of antibody development and provide new treatment options for various diseases.

   Company Address: 2100 East 54th Street North Sioux Falls 57104 SD
   Company Phone Number: 679-6980   Stock Exchange / Ticker: NASDAQ SABS
   SABS is expected to report next financial results on April 13, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


SAB Biotherapeutics Implements Reverse Stock Split to Catapult its Immunotherapy Platform and Bolster Investor Interest

Published Tue, Jan 2 2024 9:30 PM UTC

SAB Biotherapeutics Announces Reverse Stock Split to Boost Investor Confidence
SIOUX FALLS, S.D., Jan. 02, 2024 - SAB Biotherapeutics, a clinical-stage biopharmaceutical company specializing in the development of a fully-human anti-thymocyte immunoglobulin (hIgG), has recently announced its decision to implement a 1-for-10 reverse stock split. This strategic move aims to...

Clinical Study

SAB Biotherapeutics Initiates Revolutionary Clinical Trial for Type 1 Diabetes Treatment, as Competitors Witness Steeper Revenue Decline

Published Wed, Nov 29 2023 12:30 PM UTC

With the increasing prevalence of Type 1 diabetes worldwide, researchers and pharmaceutical companies are constantly striving to develop effective disease-modifying treatments. In a significant development, SAB Biotherapeutics has announced the commencement of the human Phase 1 clinical trial with SAB-142, a potential game-changer in the field. This clinical trial marks a cr...

Sab Biotherapeutics Inc

Sab Biotherapeutics Inc. Faces Crisis as Top-line Plummets by -64.695% in Q3 2023

Sab Biotherapeutics Inc, a leading biotechnology company, has recently released their financial results for the fiscal interval ending September 30, 2023. Despite certain challenges, the company has shown promising signs of improvement.
The company's earnings per share (EPS) for this period have improved significantly. Compared to a loss of $0.16 per share a year ago, Sab Biotherapeutics Inc managed to decrease their loss to $0.10 per share. Additionally, their income per share has also improved from a loss of $0.14 per share in the previous reporting season. These figures indicate that the company has made strides in reducing their losses and improving their financial performance.

Sab Biotherapeutics Inc

SABS Shocks Investors with Devastating 98.653% Revenue Plunge in Q2 2023

Shocking Figures: SABS Declares Disastrous Q2 2023 Results
In a surprising turn of events, Sab Biotherapeutics Inc (SABS) has recently announced their dismal financial results for the second quarter of 2023, leaving investors puzzled and concerned. The revenue for this period has plummeted dramatically by a staggering -98.653%, reaching a mere $0.09 million. This colossal decline can be directly attributed to a sharp drop in demand and unfavorable market conditions. Comparatively, during the same reporting season last year, the company generated $0.58 million in revenue, illustrating the severity of the decline.
Adding to the concerns, SABS' net loss per share has further widened to $-0.14, compared to $-0.15 per share in the preceding quarter. This represents a worrying trend for shareholders, as the company continues to struggle with profitability. With a net loss of $-6.881 million for the quarter, the situation appears to have deteriorated compared to the previous year when the loss stood at $-4.776 million.

Sab Biotherapeutics Inc

Record Losses and Dismal ROI Fuel Investor Concerns

Investors beware, as Sab Biotherapeutics Inc is not showing any signs of turning its financial situation around anytime soon. The company recently disclosed their disastrous fiscal period, with record losses reported of $-27 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -75.57%. This is a cause for deep concern for investors as it indicates that the company has not been able to generate profits from its operations.
The company's position in the healthcare sector is also concerning, as there are 628 other companies that have a higher return on investment. Furthermore, the total ranking for Sab Biotherapeutics Inc has deteriorated significantly, falling from 0 to 3408 in the fourth quarter of 2022. This shows that the company has not been able to keep up with its competitors and is lagging far behind when it comes to generating profits.


Sab Biotherapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com